Medicaid VBPs for Patients Act
- Last Action
- 12/19/2024
Actions
- 2024-12-19Placed on the Union Calendar, Calendar No. 768.
- 2024-12-19Committee on Ways and Means discharged.
- 2024-12-19Committee on Ways and Means discharged.
- 2024-12-17Referred to the Subcommittee on Work and Welfare.
- 2024-11-18House Committee on Ways and Means Granted an extension for further consideration ending not later than Dec. 19, 2024.
- 2024-11-18Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-743, Part I.
- 2024-11-18Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 118-743, Part I.
- 2023-05-24Ordered to be Reported (Amended) by the Yeas and Nays: 31 - 19.
- 2023-05-24Committee Consideration and Mark-up Session Held.
- 2023-05-17Forwarded by Subcommittee to Full Committee (Amended) by the Yeas and Nays: 16 - 11 .
- 2023-05-17Subcommittee Consideration and Mark-up Session Held.
- 2023-05-15Referred to the Subcommittee on Health.
- 2023-04-18Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2023-04-18Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- 2023-04-18Introduced in House
Showing 15 of 16 actions. Full history on Congress.gov.
CRS Summary
As of 2023-04-18 (00)
Medicaid VBPs for Patients Act or the MVP Act
This bill provides statutory authority for regulations that allow for the use of varying best price points under value-based purchasing arrangements for purposes of the Medicaid Drug Rebate Program. (Value-based purchasing arrangements refer to arrangements in which the price of a drug is linked to clinical outcomes; such arrangements are particularly used for new high-cost treatments, such as gene therapies.)
The Government Accountability Office must study the impact of value-based purchasing arrangements on federal health care programs, including with respect to the bill's changes.
Additionally, the bill (1) exempts sales of drugs that are made under value-based purchasing arrangements from calculations of the manufacturer average sales price for purposes of payments under Medicare medical services, if the manufacturer reports multiple best prices under Medicaid in accordance with the bill's changes; and (2) requires the Centers for Medicare & Medicaid Services to establish a program under which state Medicaid programs may cover drugs in inpatient settings via value-based purchasing arrangements.
The bill's changes terminate five years after enactment; any value-based purchasing arrangements that are in effect as of the date of termination continue to apply.
Cosponsors (20)
- ANNA ESHOO (D-CA)
- John Joyce (R-PA)
- Jake Auchincloss (D-MA)
- Mariannette Miller-Meeks (R-IA)
- Scott Peters (D-CA)
- Eric Swalwell (D-CA)
- Dan Crenshaw (R-TX)
- Gus Bilirakis (R-FL)
- Neal Dunn (R-FL)
- Troy Balderson (R-OH)
- Dean Phillips (D-MN)
- Ami Bera (D-CA)
- Ted Lieu (D-CA)
- MIKE THOMPSON (D-CA)
- Mikie Sherrill (D-NJ)
- Chrissy Houlahan (D-PA)
- Earl Carter (R-GA)
- Josh Gottheimer (D-NJ)
- Troy Carter (D-LA)
- A. Ferguson (R-GA)
Subjects
- Administrative law and regulatory procedures
- Congressional oversight
- Department of Health and Human Services
- Government studies and investigations
- Health care costs and insurance
- Intergovernmental relations
- Medicaid
- Prescription drugs
Sourced from Congress.gov (public domain).
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.